Fulltext

Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations

Abdullah MI 1 , Junit SM 1 , Ng KL 2 , Jayapalan JJ 3 , Karikalan B 4 , Hashim OH 1

Affiliations 

  • 1 Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
  • 2 Department of Surgery, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
  • 3 University of Malaya Centre for Proteomics Research, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
  • 4 Perdana University, Jalan MAEPS Perdana, Serdang 43400, Selangor, Malaysia
Int J Med Sci, 2019;16(3):450-460.
PMID: 30911279 DOI: 10.7150/ijms.29935

Abstract

Papillary thyroid cancer (PTC) is the most prevalent form of malignancy among all cancers of the thyroid. It is also one of the few cancers with a rapidly increasing incidence. PTC is usually contained within the thyroid gland and generally biologically indolent. Prognosis of the cancer is excellent, with less than 2% mortality at 5 years. However, more than 25% of patients with PTC developed a recurrence during a long term follow-up. The present article provides an updated condensed overview of PTC, which focuses mainly on the molecular alterations involved and recent biomarker investigations.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications